Advances in Cell Replacement Therapies for Diabetes
Diabetes · 01.07.2025 · 74 (7) · 1068-1077
DOI: 10.2337/db25-0037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, online erschienen am 24.04.2025. Verfasst von Bernhard J Hering und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Schulze Diabetes Institute, University of Minnesota Medical School, Minneapolis, MN. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Insulin-Secreting Cells. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAID NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Islet cell replacement therapies have evolved as a viable treatment option for type 1 diabetes complicated by problematic hypoglycemia and glycemic lability. Refinements of islet manufacturing, islet transplantation procedures, peritransplant recipient management, and immunosuppressive protocols allowed most recipients to achieve favorable outcomes. Subsequent phase 3 trials of transplantation of deceased donor islets documented the effectiveness of transplanted islets in restoring near-normoglycemia, glycemic stability, and protection from severe hypoglycemia, with an acceptable safety profile for the enrolled high-risk population. Health authorities in several countries have approved deceased donor islet transplantation for treating patients with type 1 diabetes and recurrent severe hypoglycemia. These achievements amplified academic and industry efforts to generate pluripotent stem cell–derived β-cells through directed differentiation for β-cell replacement. Preliminary results of ongoing clinical trials suggest that the transplantation of stem cell–derived β-cells can consistently restore insulin independence in immunosuppressed recipients with type 1 diabetes, thus signaling the profound progress made in generating an unlimited and a uniform supply of cells for transplant. Avoiding the risks of chronic immunosuppression represents the next frontier. Several strategies have entered or are approaching clinical investigation, including immune-isolating islets, engineering immune-privileged islet implantation sites, rendering islets immune evasive, and inducing immune tolerance in transplanted islets. Capitalizing on high-dimensional, multiomic technologies for deep profiling of graft-directed immunity and the fate of the graft will provide new insights that promise to translate into sustaining functional graft survival long-term. Leveraging these parallel progression paths will facilitate the wider clinical adoption of cell replacement therapies in diabetes care. Article Highlights Transplantation of deceased donor–derived primary human islets has restored near-normoglycemia and protection from severe hypoglycemia in immunosuppressed recipients with type 1 diabetes. Transplantation of embryonic stem cell–derived β-cells has restored insulin independence in immunosuppressed recipients with type 1 diabetes. Clinical trials are underway and planned to evaluate the safety and efficacy of transplantation of mature stem cell–derived β-cells with transient, local, minimal, and/or no-maintenance immunosuppression in recipients with type 1 diabetes. The high-dimensional, multiomic monitoring of immunity to transplanted islets and of the fate of the islet graft will faciliate the identification of determinants of sustained islet graft function and of patients most likely to benefit from cell replacement therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Schulze Diabetes Institute, University of Minnesota Medical School, Minneapolis, MN.
- Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, and Institute for Diabetes, Obesity & Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
- Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.
- Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO.
- Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL.
- George W. Woodruff School of Mechanical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.
ORCID-Profile: Bernhard J Hering, Michael R Rickels, Melena D Bellin, Jeffrey R Millman, Andrés J García, Cherie L Stabler, Peng Yi, A M James Shapiro
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
Zitieren
APA
Hering, B. J., Rickels, M. R., Bellin, M. D., Millman, J. R., Tomei, A. A., García, A. J., Shirwan, H., Stabler, C. L., Ma, M., Yi, P., Luo, X., Tang, Q., Ramachandran, S., Oberholzer, J., Ricordi, C., Kieffer, T. J., & Shapiro, A. M. J. (2025). Advances in Cell Replacement Therapies for Diabetes. Diabetes, 74(7), 1068-1077. https://doi.org/10.2337/db25-0037
Vancouver
Hering BJ, Rickels MR, Bellin MD, Millman JR, Tomei AA, García AJ, et al. Advances in Cell Replacement Therapies for Diabetes. Diabetes. 2025;74(7):1068-1077. doi:10.2337/db25-0037
BibTeX
@article{Hering2025,
author = {Hering, Bernhard J and Rickels, Michael R and Bellin, Melena D and Millman, Jeffrey R and Tomei, Alice A and García, Andrés J and Shirwan, Haval and Stabler, Cherie L and Ma, Minglin and Yi, Peng and Luo, Xunrong and Tang, Qizhi and Ramachandran, Sabarinathan and Oberholzer, Jose and Ricordi, Camillo and Kieffer, Timothy J and Shapiro, A M James},
title = {Advances in Cell Replacement Therapies for Diabetes},
journal = {Diabetes},
year = {2025},
volume = {74},
number = {7},
pages = {1068--1077},
doi = {10.2337/db25-0037}
}
EUVIMED